Bluebird Bio Announced Long-Term Follow-Up Data Continue To Support Beti-Cel As Potentially Curative Gene Therapy For Β-Thalassemia Patients Who Require Regular Transfusions Through Achievement Of Durable Transfusion Independence And Normal Or...
Bluebird Bio Announced Long-Term Follow-Up Data Continue To Support Beti-Cel As Potentially Curative Gene Therapy For Β-Thalassemia Patients Who Require Regular Transfusions Through Achievement Of Durable Transfusion Independence And Normal Or...
Bluebird Bio Announced Long-Term Follow-Up Data Continue To Support Beti-Cel As Potentially Curative Gene Therapy For Β-Thalassemia Patients Who Require Regular Transfusions Through Achievement Of Durable Transfusion Independence And Normal Or Near-Normal Adult Hb Levels At ASH Meeting
bluebird bio宣佈長期跟蹤數據顯示，Beti-Cel作爲潛在的治癒性基因治療對需要定期輸血的β-地中海貧血患者具有支持性，通過實現持久的輸血獨立性和正常或接近正常的成年Hb水平在ASH會議上取得了成果。
bluebird bio, Inc. (NASDAQ:BLUE) today announced updated data from patients with beta-thalassemia who require regular blood transfusions treated with betibeglogene autotemcel (beti-cel, approved commercially as ZYNTEGLO) in clinical studies. The data was presented today at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition.
bluebird bio公司（納斯達克：BLUE）今天宣佈了關於需要定期輸血的β地中海貧血患者在臨床研究中使用比替貝格洛基自體細胞（beti-cel，商業批准名爲ZYNTEGLO）的更新數據。該數據今天在第66屆美國血液學會（ASH）年會及博覽會上發表。
Long-Term Follow-Up Data Continue to Support Beti-Cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels
長期跟蹤數據顯示，Beti-Cel作爲潛在的治癒性基因治療對需要定期輸血的β-地中海貧血患者具有支持性，通過實現持久的輸血獨立性和正常或接近正常的成年Hb水平。
Treatment effects sustained through long-term follow-up of beyond 10 years in the earliest treated patients (n=2); 81% of participants have >5 years of follow-up
在最早接受治療的患者（n=2）中，治療效果在超過10年的長期跟蹤中得以維持；81%的參與者的隨訪超過5年。
